Home / Transcripts / IMCD N.V. (IMCD) · July 30, 2025

IMCD N.V. (IMCD) Earnings Call Transcript

July 30, 2025

Euronext Amsterdam NL Industrials Trading Companies and Distributors earnings 54 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the IMCD Half Year 2025 Results Conference Call. Marcus Jordan, CEO, and Hans Kooijmans, CFO, are hosting today's session. <<operator_script>> At this point, I'll hand things over to Marcus Jordan. Mr. Jordan, the floor is yours.

Marcus Jordan executive
#2

Thanks so much, Elba. Morning, everyone, and a very warm welcome to the analyst call for our 2025 half year results. I'm Marcus Jordan, and joining me today is our CFO, Hans Kooijmans, to discuss the 2025 half year results, which came out in the press release earlier this morning. Global economic uncertainty and tariff discussions across all regions largely shaped the first half of 2025, and that had a significant impact on customer behavior. If you look at our numbers for the first half of 2025, the summary is that we got off to a good start to the year, as you saw in the Q1 numbers. And after that, demand generally softened in the second quarter. A summary of our financial results is on Slide 4. Gross profit rose to EUR 634 million, up 7% on a constant currency basis. EBITA increased to EUR 275 million, up 4% on a constant currency basis. Our free cash flow of EUR 173 million came in lower than in the first half of 2024, mainly because of higher inventory levels. Those higher inventory levels stem from the ongoing uncertainty in the market. And as I said earlier, customer demand generally softened during the second quarter.

Marcus Jordan executive
#3

The upshot is that inventories now sit at a level that's too elevated, and we're taking active steps to bring them down. Later on in this call, our CFO Hans Kooijmans will go into working capital in greater depth. Turning to M&A: having spoken on the Q1 call about a healthy pipeline, I'm glad to report that during this year's second quarter we announced 4 acquisitions. Those deals were nicely spread across all 3 regions and business groups. First, 2 acquisitions in Spain within the food and nutrition market, involving Ferrer and TECOM. Previously, our footprint in Spain's food and nutrition ingredients market had been comparatively modest. So these 2 complementary acquisitions make us very happy indeed. We also announced the acquisition of <<inaudible>> to bolster what we offer the advanced materials industry in Chile, along with the acquisition of Trichem to speed up our growth in India's pharmaceutical market. Beyond those M&A announcements, we were glad to complete the purchase of Daoqin in food and nutraceutical ingredients in China and YCAM in personal care and pharmaceuticals in Korea — both had already been signed and announced in December 2024. We additionally exercised the call options to pick up the remaining 30% of Sunrise in China and Megasetia in Indonesia.

Marcus Jordan executive
#4

After laying out our 6 strategic growth pillars, which we shared at our Investor Day in Milan last year, I'm glad to report on some of the progress we've made in those areas. One thing we're especially proud of is the expanded rollout of the sales assistant product recommendation tool, which helps our people quickly pinpoint the right solutions for customers. That tool has now been deployed internally across all business groups, and externally in a couple of our business groups through MyIMCD. As is a core strength of IMCD, we've also kept building new business, with a number of supplier wins and expansions in the first half of the year. And after developing our APAC region successfully over the last 3 years, we recently announced that Andreas Igerl has been appointed President, EMEA and Head of our Industrial business groups. This new position was created to further drive best practices and growth throughout the region and across industrial markets. To sum up, in challenging and unpredictable macroeconomic market conditions, the resilience of our asset-light business model gives me confidence that we achieved growth in the first half of the year, and I'm thankful to our teams for their hard work and continued focus.

Marcus Jordan executive
#5

Even with these tough conditions still in place, we’re set up well for what lies ahead thanks to our portfolio that leads in specialty focus, our broad geographic and market reach, and our sophisticated digital and supply chain capabilities. At this point I’d like to pass things to Hans Kooijmans, our CFO, for an update on the figures.

Hans Kooijmans executive
#6

Thank you for that introduction, Marc. Good morning, everyone. I'd like to begin on Page 8 of the presentation, where you'll see a summary of the key figures from the first half year press release we issued earlier today. As you can see, ForEx adjusted revenue rose 6%, combining 2% organic growth with 4% from the impact of including acquisitions for the first time. The increase in ForEx adjusted gross profit was slightly higher than the revenue increase, at 7% versus the same period last year. That increase combined 4% from the first-time inclusion of acquisitions and 3% organic growth. As Marcus mentioned, we started the year strong with 6% organic growth in the first quarter, followed by modest organic growth in the second quarter. And as mentioned, demand softened as this year progressed because of ongoing tariff discussions and the related uncertainty, which significantly affected customer demand. Furthermore, weakening of currencies such as the U.S. dollar did not help and had a negative impact on the absolute amount of revenue and gross margin.

Hans Kooijmans executive
#7

Overall, considering the market environment, we're pleased to share that organic gross profit grew during the first half of 2025. When you look at gross profit as a percentage of revenue, it rose 0.2 percent point to 25.6%. That percentage gain came from a mix of product mix, acquisition effects, shifts in local market conditions, and an ongoing internal process to improve gross margin. ForEx adjusted operating EBITDA, shown on the following line, was up 4%. That rise reflected modest organic growth combined with a positive contribution from acquisitions of close to 4%. Operating EBITA as a percentage of revenue fell to 11.1% in the first half of '25. The conversion margin stood at 43.4%, which is a decline of 1.1 percent point versus the same period a year earlier. This drop in conversion margin results from higher gross profit being slightly more than offset by organic and cost growth driven by inflation. Speaking of cost at the bottom of the slide, you'll see IMCD has roughly 5,300 full-time employees. Versus the end of June last year, we brought on 263 new colleagues, reflecting acquisitions completed in the last 12 months.

Hans Kooijmans executive
#8

Like we said on earlier calls, we've been cautious—and we remain cautious—about filling open positions or bringing on new hires. Page 9 gives you some additional detail on how gross profit, EBITA and conversion margin moved year over year within each operating segment. The variances, though, break down into organic, acquisition and currency effects. In the first column, EMEA posted 3% gross profit growth on a ForEx-adjusted basis, and that wasn't enough to offset the cost increase in the segment. So as a result, the ratios tied to operating EBITDA and EBITA each came down somewhat versus the same period a year ago. Market conditions proved tough. Demand was weak throughout this segment. Even with those difficult conditions, we held our gross margin percentage in EMEA at 27.5%. That 27.5% remains well above the group average. In the Americas, we enjoyed a strong first quarter, with double-digit organic growth, and gross profit and EBITDA growth came along with it, before a second quarter that was much softer. The weakening of the U.S. dollar and other currencies in the region, together with softer demand stemming from macroeconomic uncertainties, were a significant negative factor in the second quarter.

Hans Kooijmans executive
#9

Strong cost discipline, together with organic growth in gross profit, produced better EBITDA and conversion margins. Asia Pacific looked fairly similar: a solid first quarter gave way to a weaker second quarter. And as in the Americas, the softening of the U.S. dollar along with other regional currencies, plus weaker demand, was a significant negative factor this quarter. On the plus side, we're glad to say that gross margin percentage and EBITDA margin both improved further in this region. Holding cost in the last column came in a touch below last year, at 0.7% of revenue versus 0.8% last year. I've now brought up currency effects several times. There's a reason: currencies were volatile during the second quarter. But that's why this volatility shows up in various spots in our figures. As you'd expect, a currency effect arose from translating balance sheet assets denominated in foreign currencies into euros, and that effect gets reported under net finance cost and OCI. I'll return to finance cost shortly. There's also an operational effect on revenue and gross profit stemming from weakening of, say, the U.S.

Hans Kooijmans executive
#10

As you know, in many countries it's fairly standard to quote and price products in dollars, then invoice in the local currency. When the dollar weakens against that local currency, the result is frequently a smaller absolute gross profit figure, since the same U.S. dollar amount yields less margin in local currency. That effect, naturally, is harder to see. Putting a figure on it is also tough, but it was certainly negative and not negligible in the second quarter. The translating of foreign currency results into the euro is what's more visible. During the first quarter of 2025, that translation effect was negligible. If you look at the second quarter, though, roughly 4% of our revenue and EBITDA was lost because of translating the ForEx result into the euro. Because of this currency translation effect, only in the second quarter we lost approximately EUR 50 million in revenue and EUR 6 million in EBITDA. The most significant drivers were the weakening of the U.S. dollar and the Indian rupee during the second quarter. My assumption is that you, as an analyst, have already estimated our expected currency translation loss and the impact on the remainder of this year for your forecast.

Hans Kooijmans executive
#11

Of course, no one can forecast where exchange rates will go from here — nor our EBITDA for this year's second half. Still, just to give you a sense of the scale, as a rough indication of the translation loss in the second half, you could take last year's second-half EBITDA and recalculate it using the rates in effect at the close of June this year. Using those data points we provided, the currency translation effect on second-half EBITDA would land at roughly EUR 12 million to EUR 15 million on the negative side. That figure then sits on top of the EUR 6 million already booked in the first half of this year. So currencies are playing an increasingly significant part in this volatile international environment. Turning to the next page, Page 10, you'll find a summary of the P&L lines from operating EBITA down to the net result for the period. The net result stands at EUR 11 million, or 7% below the same period a year earlier, chiefly because of higher net finance cost. Before I go into that cost increase, a few general comments on the other lines.

Hans Kooijmans executive
#12

Intangible asset amortization, along with noncash expenses tied to amortizing supplier relations, distribution rights, and other intangibles. That rise stems primarily from acquisitions we completed. Next, EUR 7 million falls under what we previously termed one-off costs, which can be divided roughly 50-50 between acquisition-related expenses and one-off organizational adjustments. Moving to the following page, Page 11, where net finance cost is broken down. As you'll notice, deferred consideration changes and currency exchange results are the primary factors behind the reported increase. On the whole, interest costs came down slightly. Currency results reflect the negative outcome of translating monetary assets and weakening foreign currencies into the euro, and it also includes IFRS hyperinflation adjustments concerning Turkey. The deferred consideration changes relate, on one side, to a negative fair value adjustment of EUR 12 million for Blumos in Chile and Valuetree in India, plus a EUR 4 million positive adjustment tied to Sunrise in China. Then on Page 12, a summary -- a high-level summary of the IMCD balance sheet. Property, plant and equipment, EUR 134 million. As always, it's a mix of, in this instance, EUR 41 million in fixed assets and EUR 93 million in right-of-use assets, meaning the items we lease must go onto the balance sheet.

Hans Kooijmans executive
#13

Of course, fixed assets remain fairly modest relative to the scale of our business, which reflects the asset-light model. After that, you can see intangible assets plus the associated deferred tax liabilities totaling roughly EUR 2.4 billion. Those stem from acquisitions completed since our listing in July 2014 and from our history as a company formerly owned by private equity. Turning to financing, there is EUR 1.5 billion of debt — I'll come back to that shortly — along with EUR 2 billion of equity. As you can see, that substantial equity position funds about 56% of our capital employed. On the next page is a summary of reported working capital, and Marcus has already mentioned that total working capital at the end of June stood at EUR 963 million, versus EUR 907 million in December last year and EUR 843 million in June last year. The overall rise reflects a combination of things: first, the working capital impact from acquisitions completed; second, a bit of tailwind from currency effects; and third, some negative effect from what I'd describe as operational developments. Translating the absolute working capital amount into days of revenue, we reported 69 days at the end of June this year, against 63 days at the end of June 2024.

Hans Kooijmans executive
#14

And that rise isn't exactly a point of pride. If you look down at the bottom of the slide, you'll notice we made progress on debtor days, which fell from 64 last year, June, to 60 days by the end of June this year. What else you can observe is that the primary force behind the growth in working capital days is a mix of higher stock days together with somewhat reduced creditor days. Most significantly, the rise in stock days is in part market-driven and in part something we brought on ourselves. When I say market-driven, I mean higher stock days stemming from customers pushing back the delivery dates of orders they had already agreed to. I've mentioned this a few times on earlier calls — the trend of more and more customers seizing the chance to take a later delivery date than was originally planned. And another factor that has grown increasingly significant is the longer time stock spends on the water, largely because of the situation in the Red Sea area. And on the internal side too, I think it's fair to say we ought to have moved faster and been more alert in buying stock so as to adapt to shifting market conditions.

Hans Kooijmans executive
#15

Marcus and I have put corrective steps in place to actively bring working capital levels down in this market, which should help get things back to somewhat more normal levels there. Then, moving to the next slide, here's a summary of our net debt position, leverage ratios, and maturity profile. As you can see, net debt went up by roughly EUR 260 million in the first 6 months, to EUR 1.5 billion. That increase was influenced by, among other things, a dividend payment of EUR 127 million that we made shortly after the AGM, and EUR 239 million of consideration paid for acquired businesses. The EUR 1.5 billion of debt includes approximately EUR 1.3 billion of bonds. At the end of June, the leverage ratio, based on IFRS and on our loan documentation, stood at 2.6x EBITDA. That level was comfortably under the maximum set out in our loan documentation. Then, on the right-hand side of this page, you can see a healthy maturity profile for our debt position. I'd like to wrap up this brief summary with a cash flow overview on Page 15. Free cash flow came in at EUR 173 million, which is a decrease of EUR 48 million versus the same period last year. The main driver, as I mentioned earlier, is the increase and the higher investment in working capital.

Hans Kooijmans executive
#16

This stemmed, as I noted earlier, primarily from elevated stock days. Capex came to roughly EUR 5 million, pretty much matching what was spent a year ago and mainly aimed at IT investments plus some modest office upgrades in lab equipment. Then, if you turn to Page 17, the outlook for this year is there, and I imagine everyone has already gone through the wording in the press release, so I won't read it out loud again. I'd now like to give it back to the operator so the lines can be opened for Q&A. Elba, over to you.

Operator operator
#17

<<operator_script>> The initial question is from Suhasini Varanasi at Goldman Sachs.

Suhasini Varanasi analyst
#18

I’ve got 2 questions, please. Could you talk a bit about what the trends look like across verticals and by region? And what was it, exactly, that slowed materially for you in the second quarter compared with the first quarter? For instance, was industrial — the case segment — the weakest one? Was Life Sciences perhaps a bit more resilient? And how do you think the recent news flow around tariff deals will affect customers’ decision-making as we go into the second half of the year? Would that added clarity basically be helpful?

Marcus Jordan executive
#19

Thanks for the questions. To start with how things are trending in the different verticals, perhaps it makes sense to look at it from a market segment angle. If we take what I'd call our strongest market first — after a soft year last year, pharma has been resilient for us and grown in both quarters. Then food and nutrition, which again we view as fairly stable. On food and nutrition, there are some specific trends we're seeing — for instance affordability, which has already been a theme for several years in Lat Am and APAC. That emphasis on affordability is now showing up in Europe and the U.S. as well, along with a focus on health, particularly from a North American and European standpoint. And in the U.S., many people of course talk about the GLP-1 type drugs. So looking at supplements and nutritionally enhanced products matters a great deal. On those food and nutrition topics, we see considerable opportunity from a formulary expertise angle too. Our labs are receiving a lot of requests in that area.

Marcus Jordan executive
#20

If you move on to the Life Science segment, I'd say the one that's been softest for us — after a really strong year last year — is Beauty Personal Care. And what we're seeing there is a lot of consumers trading down. I think we all hear plenty about how influencers and the contract manufacturers are having an impact. And basically, the big hit that's showing up from a premium beauty standpoint. I think, again, positively for us, these influencers and the contract manufacturers, they lean more on external parties such as IMCD, to help them from a formulator perspective. But as with all of these reformulations, it does take time. Moving on to the Industrial segment. I think in general, you can characterize it by generally having soft demand during the second quarter. If you look at things like the coatings and construction, particularly from a domestic perspective, things like the plastics industry, I think we all read about the automotive industry struggling, flexible packaging down. There are some bright spots. I think that if you look again at that plastics market, things like the medical market continues to be quite robust, as does the wire and cable, I think as technology and IT demands continuing to grow.

Marcus Jordan executive
#21

Hopefully that leaves you with a solid sense of things from a market standpoint. Then, shifting to a geographic view: beginning with the Americas, I'd describe Q1 as a really encouraging, robust opening to the year. That said, one point matters here — the comparison, the comp, for Q1 against Q2: Q1's comp was far easier. Even so, we did observe some softening and a slowdown throughout the region. I believe that stems from the reasons Hans referenced — clearly tied to the persistent broader market uncertainty, and that word uncertainty comes up constantly with customers, who are essentially, I think, genuinely anxious about predicting what lies ahead or making commitments of any sort, especially when it comes to their own investment plans. So that uncertainty showed up region-wide, fueled by tariffs, and naturally currency played a sizable role too. In Europe, much like APAC — I mean the whole — all 3 regions face uncertainty. But in Europe it was quite a mixed picture: certain countries did rather well while others came in rather soft. And I think that really speaks to the diversity we have as a company, since we aren't heavily dependent on any single country or market.

Marcus Jordan executive
#22

Now, turning to APAC. What really stood out, I'd say, was performance that beat our expectations outside of Beauty Personal Care in China. And India, while it stays a very interesting and important country for us, saw a bit of a growth slowdown. And as Hans mentioned, there was an impact there from a currency perspective. Does that answer your question?

Suhasini Varanasi analyst
#23

Yeah, that's really helpful. But when you look ahead toward the second half, now that we've gotten some news flow about tariff deals, are you seeing any better clarity or certainty from your customers?

Marcus Jordan executive
#24

Honestly, it feels a bit soon to say much about that. Still, to return to what I said before: when we talk with customers, their number one worry has been not knowing what will happen, especially regarding tariffs. Over the last few days in particular, we've clearly started to see some clarity arrive, hopefully. So let's stay hopeful and optimistic that this will produce a favorable effect. Even so, I'd say it's still slightly too soon for us to give specifics.

Operator operator
#25

Annelies Vermeulen from Morgan Stanley has the next question.

Annelies Vermeulen analyst
#26

I've got 2 questions, if I may. First, I believe when we spoke earlier in the year, we discussed pricing mostly settling down, driven in part by volume beginning to recover and displaying a bit of resilience. In light of the softer volumes you've experienced in Q2 and up to now, and what looks like a fairly volatile earnings season on the supplier side, could you speak to pricing during Q2 and as we move into Q3, and whether you've noticed any meaningful pricing erosion yet? Second, again given the softer growth and operating profit in Q2, I understand the volume element is hard to forecast, but maybe you could address the cost base. Do you intend to make any adjustments for the second half should that volume softness continue?

Marcus Jordan executive
#27

Thank you, Annelies. On the pricing side, I'd say I'm fairly optimistic, because we're seeing more of a general market environment come back—one where it really varies product by product. Some products are seeing price increases, while others—more toward the semi-specialty, semi-commodity end—are facing greater pricing pressure. As you know, we're about 85% specialty, so that pricing pressure doesn't hit us as hard. Overall, though, I'd describe the pricing conditions in play as more normal. On the cost side, as Hans said, we're being very prudent and careful about replacing people when they retire, and we're looking at items such as exhibition costs, travel costs, and so on. So across the business, we're really raising awareness around cost consciousness. I also think it matters that we keep investing—take the digitalization and IT investments we make, for instance, including things like the sales assistant I mentioned in my prepared remarks. We see those as genuine differentiators, and we think it's important to be able to offer that true omnichannel way of working with the customer base and with our principles.

Marcus Jordan executive
#28

It genuinely drives stickiness, and we see that as a differentiator — something that matters a great deal for growth over the long term. Of course, we also have the lever on the bonus side. That's something we can keep examining and assess market by market.

Operator operator
#29

Our next question is from David Kerstens at Jefferies.

David Kerstens analyst
#30

I've got 2 questions, if I may. First, you mentioned the momentum in Asia Pacific that came through in the second quarter. That may be partly due to a tougher comparison, but it was also comparatively weaker than the other regions. Does that match what you're seeing across the overall market? And are you also seeing more competition coming increasingly from local Chinese distributors? My second question concerns the M&A spend. Hans, you pointed to EUR 239 million in the first half. That seems relatively high compared with the acquired revenues of EUR 200 million, but you also mentioned exercising the call options for Megasetia and Sunrise. Could you quantify that effect? And excluding those call options, what would the multiple be?

Hans Kooijmans executive
#31

David, maybe I should handle the second question first, and Marcus is still working through the first one, since I’m not certain we’ve fully grasped what was asked. When you look at the call option we exercised for the 2 acquisitions we completed, that was essentially already a debt position in my net debt schedule under short term, and we more or less paid for it. Back to your question on the multiples we paid, they were basically always within the range we shared with you previously, so somewhere between 7 and 11x EBITDA. So there’s no particular uptake or outline. I think the only thing we mentioned when issuing a press release is that we don’t disclose the profit level of the companies we buy. We often tell you that if there is no news in the press release about specifics on the financial side, you should assume somewhere between 8% and 10% EBITDA margin. And we only made an exception there when we announced the Trichem Pharma acquisition in India, where we said the revenue was EUR 16 million and about 1/3 of that revenue is commission income. And that indicates that there is a profit level that is much higher than the on average 8% to 10% of EBITDA.

Hans Kooijmans executive
#32

That answer is maybe on the long side and still not very specific, but there's nothing unusual about the multiples.

Marcus Jordan executive
#33

And then, David, in connection with what you asked, the easier comp I mentioned was referring to the Americas region. But regarding your question about whether we're seeing more competition coming from China — well, China has, of course, always been what I'd call a fierce competitor. What the tariffs have done, in some cases, I think, is perhaps shift where that competition shows up. Some of the more remote countries, Brazil being an example, I would say. Again, mostly on the semi-specialty semi-commodity products, we're seeing more Chinese competition. But our portfolio is largely protected, again, through that specialty focus and the need for formulator approval. So it's not as though products can be easily interchanged. Does that answer your question?

David Kerstens analyst
#34

Yeah, just one quick follow-up, perhaps, regarding the EUR 239 million. To be completely clear, then, that figure leaves out the call options tied to the larger stake you exercised in...

Hans Kooijmans executive
#35

Sorry — go ahead, David.

David Kerstens analyst
#36

Including it — the amount was limited.

Hans Kooijmans executive
#37

Honestly, I can't pull the precise figure from memory right now, but it formed a piece of the short-term deferred consideration net debt position as of the close of last year. Still, I'd rather not put a number out there on this call.

Marcus Jordan executive
#38

There's a figure I'm thinking of, though I can't say for certain whether it represents the full count for the 2.

Operator operator
#39

Our following question is from Carl Raynsford at Berenberg.

Carl Raynsford analyst
#40

Three things from me, if that's alright. First, regarding what you said about stock days and delivery delays — does that imply those orders that were pushed back are merely postponed rather than lost, meaning you'd pick up the benefit on revenue in subsequent quarters? If so, would that impact be material? And do you therefore see growth as uneven from quarter to quarter across the year? Second, if I could return to APAC once more, please. Could you perhaps shed some light on which end markets were softer and which were stronger there in Q2, the ones affected by customer demand? I'm simply attempting to reconcile that negative organic gross profit figure with the robust pharma growth you mentioned. And finally, on the Americas, at a really high level, any color on how Latin America and the U.S. performed within that broader region would be extremely helpful?

Hans Kooijmans executive
#41

Yes. Carl, regarding your first question about how customers are affected when an order's delivery date slips: we're talking here about orders customers have committed to. Customers always have the flexibility to split an order or essentially revise the agreement on any given day. What we observe during uncertain times is that customers take advantage of that option more and more. And increasingly often, I have to say, it isn't simply a matter of pushing things back by one or 2 days or 2 weeks, including the delivery days themselves. As you can imagine, we're then the party holding the stock for those customers, which affects the absolute amount of inventory we carry on the balance sheet. So it sits in stock where we don't bear an economic risk and merely have to finance it. When customers do this frequently, naturally, you factor it into the prices you set for them. So we hope to be compensated for that. We also hope that offering them this flexibility helps build healthy, strong intimacy and a solid relationship with that customer.

Hans Kooijmans executive
#42

Every so often — and as a finance guy, this gets on my nerves when it does — it happens.

Marcus Jordan executive
#43

Then, Carl, on your questions about APAC and the Americas — maybe we start with the Americas. I don't want to get into individual countries specifically. But I think it's fair to say you can imagine that with the tariffs, the U.S. and Canada, I would say, were especially hit, with consumers not knowing what pricing for their products would be pretty much the next day or the next week. So I'd say those comments about consumer confidence apply particularly to the U.S. and Canada. In Latin America, it was pretty much a mix, where we saw some countries doing well in the second quarter, but quite a bit of softness in Brazil, as an example. But again, nothing really specific to note there. And on APAC, regarding the gross margin percentage, again, nothing specific to particularly note — more related to product mix. I mean, you mentioned the pharmaceutical market there, but I also did mention Beauty Personal Care, as an example, being quite soft, and you could imagine that the gross profit percentage of Beauty Personal Care could be quite high.

Operator operator
#44

Luuk Van Beek of Banque has the next question.

Luuk van Beek analyst
#45

I've got a question regarding costs versus revenues when you look at them on an organic basis. Looking at Q2, revenues on an organic basis came in flat, yet operational EBITA went down. So I was wondering whether the organic cost increase, in spite of those revenues, came from things like seasonal fluctuations, whether any temporary effects were at play, or whether you're broadly seeing that offsetting cost inflation through rising revenues and gross margins is quite difficult?

Hans Kooijmans executive
#46

Luuk, what you’re seeing in our cost structure is mostly people — that’s the sales infrastructure we have, plus the related support staff. As Marcus mentioned, we’ve been fairly consistent about being careful when filling vacancies there, but we do need to keep the sales structure in place. And then what you see is that if you have a sales force — basically, what I could say is that we have a sales force that at the moment could do more than what they did in the second quarter. And then yes, you don’t — you are — you see inflation showing up in your annual salary increases and these type of things. And to cover these costs that will stay there during the year, you need to grow your top line, and you need to grow your margin. And in a quarter where you don’t have sufficient organic growth and then you see a decrease on your ratios. And let’s hope that the second — maybe the third and the fourth quarter, that we will see organic growth again to compensate for these costs there. And there is a bit of flexibility, as Marcus indicated, on the bonus lines that could kick in, in the second half of the year.

Hans Kooijmans executive
#47

But we’ll see how that plays out. My hope is that we’ll need the full bonus amount—the level people receive when they hit the target.

Marcus Jordan executive
#48

Perhaps I can just add one more point—maybe also worth adding. When you consider how the industry overall is consolidating and the patterns we observe among suppliers, our focus is squarely on growth over the long term and on truly ensuring we have the right organization in place, not just for today but to draw suppliers in the future. So that's a balance we genuinely take very seriously from a cost-control standpoint, while also not examining it specifically quarter by quarter. Rather, what do we require for that long-term growth and, again, the traction that makes suppliers want to work with us going forward.

Operator operator
#49

Our following question is from Eric Wilmer at Van Lanschot Kempen.

Eric Wilmer analyst
#50

I have a few questions. One of the larger acquisitions you've made recently was Spanish Ferrer element, as shown—judging from the portfolio, this looks mainly like a dairy-based business, which doesn't seem to fall within our core areas of expertise. So could you maybe walk us through your rationale for this deal, apart from growing in Spain spend, and perhaps your future margin profile in that region? And what are your expectations for M&A in H2, particularly given valuations that are somewhat depressed at the moment? And maybe lastly, to what extent are you sensing perhaps unsustainable under investment by your industrial customers? Or is it really soft demand that's primarily driving—yes, that's primarily driven by weak overall and consumer demand. So to what extent is it the consumer, or perhaps unsustainable under investment by your customers?

Marcus Jordan executive
#51

Eric, thanks so much for those questions. To start with Ferrer, we were especially pleased to complete that acquisition, since our Food and Nutrition operation in Spain was fairly small overall. You're absolutely right about that. On a worldwide level, dairy isn't among our bigger lines of business, so to speak, or subsegments inside the Food and Nutrition area. Even so, we see it as a very compelling submarket. I'd say this deal is a good illustration of an acquisition through which we hit a couple of key goals. The first was genuinely bolstering our team in Spain, which gives us a really strong footprint so we can then accelerate organic growth in Food and Nutrition there, and beyond that, from a worldwide standpoint, we can learn from Ferrer about what they do on the dairy side, come to understand it, and then ideally spread that knowledge base much more widely. So for us, Ferrer — and don't let what you might see in that product portfolio mislead you. That portfolio contains plenty of specialties, and we'd be quite enthusiastic about growing them further from a geographic standpoint. As for H2 on the acquisition front, the pipeline we have stays healthy.

Marcus Jordan executive
#52

I'd say overall we're about as active as we have ever been, at least when it comes to talking with prospective sellers and cultivating those relationships over the long haul. It's fair to say that in certain instances those conversations are running longer, since the valuation is, as you can imagine on our end, somewhat harder to pin down. As you've seen, earn-out mechanisms are being used by us increasingly, which we believe protects us while also giving the seller an incentive to still potentially sell and, hopefully, when the business grows afterward, they capture the upside. But yes, broadly speaking, the pipeline is still healthy. And regarding industrial underinvestment versus demand, I think it's genuinely hard to judge at this point, because, again, in talking with various customers, this has simply been such an uncertain stretch due to the tariffs that people have felt nervous about investing. I think we read a lot about that in the press. Hopefully, as we discussed earlier on the call, once tariffs become much clearer and more solidified, we'll gain better visibility into what investments will be made and where.

Operator operator
#53

Our following question is from Chetan Udeshi at JPMorgan.

Chetan Udeshi analyst
#54

Marcus and Hans, this one leans more toward strategy, and it matters not only for IMCD but for some of your competitors as well. Looking at how your earnings have moved, organic EBITDA fell last year. Organic EBITDA also dropped the year before that. So for '23 and '24 — and based on what you've shared with us for Q2 — it's possible this could be yet another year of earnings decline. What I'm wondering is whether you believe the structural trends in this industry have shifted, because my assumption is that when you're putting so much OpEx — so much money into organic OpEx growth — the goal is to grow the business through the cycle, not only when conditions are favorable but also when they aren't, and that ought to be the objective, yet we don't appear to be witnessing that, at least not consistently across the last 3 years. So I'm curious whether you think the industry structure has changed — you mentioned more competition from China and certain pockets of your business? And if that is a structural change, how are you adapting your business to it?

Marcus Jordan executive
#55

Thanks for asking that. No, I really don’t see the industry structure having shifted in any major way overall. When you look at the distribution landscape broadly, consolidation is still ongoing. But perhaps what matters even more is consolidation on the supplier side — where the share of business they outsource is typically rising, and they also want to partner with bigger players like IMCD, while stepping away from, say, small family-run businesses, since those firms can’t keep pace with digitalization topics, sustainability topics, and so on. So I don’t see any big structural change. The momentum, I believe, is still very much on our side. Of course, you’re quite right about the decline in ’23 and ’24. Let’s hope that isn’t the case in ’25. But if you look at the reasons before that, the reasons were very different and, I’d say, exceptional. So let’s hope we don’t keep facing exceptional circumstances. Still, I believe the business model remains very robust and intact. The trends we’ve observed for many years, I think, keep building. And I think we’re very well positioned for the future.

Marcus Jordan executive
#56

What we really need, I'd say, are macroeconomic conditions that are more generally stable. Does that address your question?

Chetan Udeshi analyst
#57

Yes.

Operator operator
#58

Nicole Manion from UBS has our final question.

Nicole Manion analyst
#59

I have just one more follow-up, if I may, regarding the cost base. I realize you have been quite explicit that you continue to be very cautious when it comes to head count. I was simply wondering whether you could offer us any indication of how your own voluntary attrition has been trending year-to-date, particularly in light of the broader environment?

Marcus Jordan executive
#60

Honestly, predicting retirements and when folks will choose to depart is really tough, unfortunately. That said, look, as I mentioned, this is a matter we examine quite closely. I'd say we seize every chance available to us. And it's something that — going forward — will keep getting our special focus. So we recognize how important it is for the cost base to stay disciplined in that area. Yet once more, weighing that against, as I noted earlier, ensuring we're genuinely well set up for the long-term future rather than merely on a quarter-by-quarter basis.

Hans Kooijmans executive
#61

Nicole and Hans, we’re not going to resort to what I’d term emergency actions right now—cutting back on digital infrastructure spending just to produce an attractive short-term cost decrease—because ultimately that investment is the key to how we’ll operate going forward. We have to bring that omnichannel offering to market. I believe we’re quite far along and doing very well. You may have seen what we presented in Milan, since that reflects what’s in the pipeline. It is now live and running. The opening now at certain market segments is already available to customers as well. And we’re receiving a fair amount of favorable feedback on that. We all hope this will lead to better cost cross-selling ratios, that we’ll sell additional products to the same customer, and that organic growth returns faster than market growth. We must continue developing here. Does that address your question, Nicole?

Nicole Manion analyst
#62

Yes. Yes, it certainly did.

Operator operator
#63

Looks like Anil Shenoy from Barclays has one final question for us.

Anil Shenoy analyst
#64

Only one, if I may. I realize you typically avoid discussing month-to-month patterns in your business. But I wanted to ask, since a lot of industrial companies have mentioned that June was really weak. So have you noticed a deceleration, particularly in June? Or would you say the Q2 slowdown has been steady across April, May and June? The reason I ask is, obviously, if there was a slowdown specifically in June, and if that carries into H2, then that would probably suggest that H2 -- there's a chance H2 could come in weaker than Q2. So any detail on the monthly trends would be really useful.

Marcus Jordan executive
#65

Thanks for asking, Anil. When we look at how Q2 went, performance was fairly steady each month across the second quarter. So to offer you some reassurance on that point, there wasn't a dramatic drop-off in June. Across the 3 months, it was very consistent.

Operator operator
#66

Having said that, I'd now like to hand things back to Mr. Jordan so he can offer any closing remarks.

Marcus Jordan executive
#67

Thanks so much, everyone, for being on the call this morning and for the questions. And yes, on behalf of Hans, I'd like to wish you a good rest of the day. Thank you all.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete IMCD N.V. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to IMCD N.V. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.